REPORT TO THE LEGISLATURE
Pursuant to P.A. 121 of 2024
Article 2, Section 604
Hepatitis C Treatment Report

Sec. 604. (1) Funds appropriated in part 1 for Hepatitis C treatment shall be used only to purchase specialty medication for Hepatitis C treatment in the prison population. In addition to the above appropriation, any rebates received from the medications used shall be used only to purchase specialty medication for Hepatitis C treatment, By February 15, the department shall issue a report for the previous fiscal year that includes all of the following:

(a) The total amount spent on specialty medication for the treatment of Hepatitis C.
(b) The number of prisoners who were treated for Hepatitis C.
(c) The amount of any rebates that were received from the purchase of specialty medication, and what, if any, outstanding rebates are expected to be received.
(d) The Hepatitis C status of all incoming prisoners and the number of prisoners who are reinfected while incarcerated and require retreatment for Hepatitis C.
(e) The number of those treated and released and then retreated upon reincarceration.

The total average monthly prisoner census for FY2024 was 32,966.

	# of Prisoners that started treatment during QTR	Total # of prisoners in treatment during QTR	# of Prisoners that completed treatment during QTR	Total expenditures during QTR	Total rebate received
1st QTR FY 2024	248	415	253	$4,065,014.20	N/A
2nd QTR FY 2024	249	411	220	$3,912,532.18	N/A
3rd QTR FY 2024	142	333	226	$2,238,709.58	($45,577.15)
4th QTR FY 2024	129	236	139	$1,970,031.51	($64,352.62)

Fibrosis Stage of Incoming, Treated Prisoners					
	Stage 0	Stage 1	Stage 2	Stage 3	Stage 4
Number of Prisoners	200	351	125	60	31